These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30028993)

  • 1. Small molecules bind human mTOR protein and inhibit mTORC1 specifically.
    Allen SA; Tomilov A; Cortopassi GA
    Biochem Pharmacol; 2018 Sep; 155():298-304. PubMed ID: 30028993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
    Weinberg MA
    Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
    Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
    Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic modeling of signal transduction by mTOR complexes in cancer.
    Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
    J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
    Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
    Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
    Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
    Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
    PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
    Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
    Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Small-Molecule Selective mTORC1 Inhibitors via Direct Inhibition of Glucose Transporters.
    Kang SA; O'Neill DJ; Machl AW; Lumpkin CJ; Galda SN; Sengupta S; Mahoney SJ; Howell JJ; Molz L; Hahm S; Vlasuk GP; Saiah E
    Cell Chem Biol; 2019 Sep; 26(9):1203-1213.e13. PubMed ID: 31231029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIS21
    Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperglycemia-induced Bcl-2/Bax-mediated apoptosis of Schwann cells via mTORC1/S6K1 inhibition in diabetic peripheral neuropathy.
    Zhu L; Hao J; Cheng M; Zhang C; Huo C; Liu Y; Du W; Zhang X
    Exp Cell Res; 2018 Jun; 367(2):186-195. PubMed ID: 29621478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
    Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
    Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes.
    Tao Z; Barker J; Shi SD; Gehring M; Sun S
    Biochemistry; 2010 Oct; 49(39):8488-98. PubMed ID: 20804212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107.
    Khor ES; Wong PF
    Int J Biochem Cell Biol; 2018 Aug; 101():64-73. PubMed ID: 29857052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
    Li X; Li Z; Song Y; Liu W; Liu Z
    Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.